Valorization of Starch to Biobased Materials

whitePaper | November 22, 2022

Specializing in oncology, anti-infective and complex formulations, Pfizer Melbourne provides end-to-end services from development through to commercial manufacture of sterile dosage forms.

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

whitePaper | March 24, 2023

The global biotech industry continues to witness growth with an estimated market size of nearly $300B, despite the current state of the funding environment

whitePaper | December 20, 2022

The current processing paradigm of large manufacturing facilities dedicated to singleproduct production is no longer an effective approach for best manufacturing practices.

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

whitePaper | March 9, 2023

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry